Cargando…
Efficacy and safety of tocilizumab in Behçet’s syndrome with refractory arterial lesions: a single-centre observational cohort study in China
OBJECTIVE: The aim of this observational cohort study was to assess the effectiveness and safety of the IL-6-receptor inhibitor tocilizumab (TCZ) in Behçet’s syndrome (BS) with refractory arterial involvement. METHODS: Ten patients admitted to the Rheumatology and Immunology Department of Peking Uni...
Autores principales: | Zhong, Hua, Liu, Tian, Liu, Yanying, Zhang, Xiaoying, Zhou, Yunshan, Su, Yin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258597/ https://www.ncbi.nlm.nih.gov/pubmed/34791076 http://dx.doi.org/10.1093/rheumatology/keab840 |
Ejemplares similares
-
Tocilizumab for refractory Castleman’s disease with paraneoplastic pemphigus and Behçet’s disease
por: Vargas, Ana Beatriz, et al.
Publicado: (2012) -
Tocilizumab in the treatment of severe and refractory parenchymal
neuro-Behçet’s syndrome: case series and literature review
por: Liu, Jinjing, et al.
Publicado: (2020) -
Successful treatment of Behçet’s uveitis with Tocilizumab
por: Alokaily, F., et al.
Publicado: (2017) -
Apremilast in Refractory Behçet’s Syndrome: A Multicenter Observational Study
por: Vieira, Matheus, et al.
Publicado: (2021) -
The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)